<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG，Biologics Innovation Group是由致力于从事生物医药领域研究、开发、应用、临床、投资等工作的独立个人，自愿组织的一个专业/非盈利性机构。正式成立于2014年，迄今会员490余人，相继举办20余场行业峰会。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 18 Feb 2021 17:04:57 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>低毒有效！“睡美人” CAR-T I/II期临床试验结果</title><link>https://mp.weixin.qq.com/s/otcr9WCq5mRU0O7I-U8kUQ</link><description></description><content:encoded><![CDATA[低毒有效！“睡美人” CAR-T I/II期临床试验结果]]></content:encoded><pubDate>Thu, 18 Feb 2021 16:50:27 +0800</pubDate></item><item><title>LILRB4，癌症和自身免疫疾病新秀靶点</title><link>https://mp.weixin.qq.com/s/rO8ZQbg24r3f5nwtM_uvlA</link><description></description><content:encoded><![CDATA[LILRB4，癌症和自身免疫疾病新秀靶点]]></content:encoded><pubDate>Mon, 15 Feb 2021 08:20:03 +0800</pubDate></item><item><title>全面开花！B7-H3的抗体靶向治疗</title><link>https://mp.weixin.qq.com/s/IcYAS6rfZYl6DKKWM68tyg</link><description></description><content:encoded><![CDATA[全面开花！B7-H3的抗体靶向治疗]]></content:encoded><pubDate>Fri, 12 Feb 2021 22:59:04 +0800</pubDate></item><item><title>Nature Immunology: PD-1作为伴随诊断，如何使用更有效？</title><link>https://mp.weixin.qq.com/s/sNrxNyAJ97INVscYcAJeIg</link><description></description><content:encoded><![CDATA[Nature Immunology: PD-1作为伴随诊断，如何使用更有效？]]></content:encoded><pubDate>Tue, 09 Feb 2021 21:10:35 +0800</pubDate></item><item><title>万字长文！自组装纳米结构siRNA递送系统</title><link>https://mp.weixin.qq.com/s/GamErUEIY3nFabjXDX2Htg</link><description></description><content:encoded><![CDATA[万字长文！自组装纳米结构siRNA递送系统]]></content:encoded><pubDate>Mon, 08 Feb 2021 09:58:30 +0800</pubDate></item><item><title>新江湖｜碧博生物加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/C3k03kF5ub0YQbihdRJ5KQ</link><description></description><content:encoded><![CDATA[新江湖｜碧博生物加入BiG会员机构！]]></content:encoded><pubDate>Mon, 08 Feb 2021 09:58:30 +0800</pubDate></item><item><title>经典永流传，单克隆抗体简史！</title><link>https://mp.weixin.qq.com/s/a-I9lfPEXUOnhKLLa3_KeQ</link><description></description><content:encoded><![CDATA[经典永流传，单克隆抗体简史！]]></content:encoded><pubDate>Fri, 05 Feb 2021 16:01:38 +0800</pubDate></item><item><title>新江湖｜锐得麦医药加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/_2zn3Y6jaNHXYBVecDyqyQ</link><description></description><content:encoded><![CDATA[新江湖｜锐得麦医药加入BiG会员机构！]]></content:encoded><pubDate>Fri, 05 Feb 2021 16:01:38 +0800</pubDate></item><item><title>Chugai制药神来之笔：肿瘤微环境抗体定向技术</title><link>https://mp.weixin.qq.com/s/UmlOGxZwuGBeXxnX9Ej7pA</link><description></description><content:encoded><![CDATA[Chugai制药神来之笔：肿瘤微环境抗体定向技术]]></content:encoded><pubDate>Wed, 03 Feb 2021 17:38:38 +0800</pubDate></item><item><title>新江湖｜戴晓兵、李成涛、李洁、何立峰加入BiG！</title><link>https://mp.weixin.qq.com/s/z7PpFRxSxWbm9AbkpdpWtw</link><description></description><content:encoded><![CDATA[新江湖｜戴晓兵、李成涛、李洁、何立峰加入BiG！]]></content:encoded><pubDate>Wed, 03 Feb 2021 17:38:38 +0800</pubDate></item><item><title>二十载IL-36：炎症与肿瘤</title><link>https://mp.weixin.qq.com/s/5rUSOsHXY7FmCxnzLyrAFw</link><description></description><content:encoded><![CDATA[二十载IL-36：炎症与肿瘤]]></content:encoded><pubDate>Wed, 03 Feb 2021 17:38:38 +0800</pubDate></item><item><title>AML治疗新策略，CD33双抗！</title><link>https://mp.weixin.qq.com/s/y4j0jgtuVILD5d6678cKjA</link><description></description><content:encoded><![CDATA[AML治疗新策略，CD33双抗！]]></content:encoded><pubDate>Mon, 01 Feb 2021 17:22:53 +0800</pubDate></item><item><title>新江湖｜益莱生物加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/ea3sqP9h4bf6PVyWQUSJbA</link><description></description><content:encoded><![CDATA[新江湖｜益莱生物加入BiG会员机构！]]></content:encoded><pubDate>Mon, 01 Feb 2021 17:22:53 +0800</pubDate></item><item><title>王晓东｜从NIBS走出的维泰瑞隆，做药的逻辑是什么？</title><link>https://mp.weixin.qq.com/s/v6A4IXS_2LCUwZf2J-rsag</link><description></description><content:encoded><![CDATA[王晓东｜从NIBS走出的维泰瑞隆，做药的逻辑是什么？]]></content:encoded><pubDate>Thu, 28 Jan 2021 18:02:49 +0800</pubDate></item><item><title>多抗潮头，创药蓝海｜第七届BiG年会来了！</title><link>https://mp.weixin.qq.com/s/qgqCame67NjttxHhUkbJzw</link><description></description><content:encoded><![CDATA[多抗潮头，创药蓝海｜第七届BiG年会来了！]]></content:encoded><pubDate>Thu, 28 Jan 2021 17:56:01 +0800</pubDate></item></channel></rss>